since cyclophosphamide is used by both oral and i.v . routes in the treatment of hematological and solid malignancies , we designed a randomized , crossover clinical trial to evaluate the pharmacokinetics of this anticancer agent after either administration route .
C1527415
used
C0013153
administration route